<?xml version='1.0' encoding='utf-8'?>
<document id="25907407"><sentence text="Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects."><entity charOffset="87-99" id="DDI-PubMed.25907407.s1.e0" text="cabozantinib" /></sentence><sentence text="Cabozantinib is a small molecule tyrosine kinase inhibitor that has been approved for the treatment of patients with progressive, metastatic medullary thyroid cancer"><entity charOffset="0-12" id="DDI-PubMed.25907407.s2.e0" text="Cabozantinib" /><entity charOffset="33-41" id="DDI-PubMed.25907407.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.25907407.s2.e0" e2="DDI-PubMed.25907407.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25907407.s2.e0" e2="DDI-PubMed.25907407.s2.e1" /></sentence><sentence text=" Cabozantinib exhibits a pH-dependent solubility profile in vitro"><entity charOffset="1-13" id="DDI-PubMed.25907407.s3.e0" text="Cabozantinib" /></sentence><sentence text=" Two phase 1 clinical pharmacology studies were conducted in healthy subjects to evaluate whether factors that may affect cabozantinib solubility and gastric pH could alter cabozantinib bioavailability: a food effect study (study 1) and a drug-drug interaction (DDI) study with the proton pump inhibitor (PPI) esomeprazole (study 2)"><entity charOffset="122-134" id="DDI-PubMed.25907407.s4.e0" text="cabozantinib" /><entity charOffset="173-185" id="DDI-PubMed.25907407.s4.e1" text="cabozantinib" /><entity charOffset="310-322" id="DDI-PubMed.25907407.s4.e2" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.25907407.s4.e0" e2="DDI-PubMed.25907407.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25907407.s4.e0" e2="DDI-PubMed.25907407.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25907407.s4.e0" e2="DDI-PubMed.25907407.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25907407.s4.e1" e2="DDI-PubMed.25907407.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25907407.s4.e1" e2="DDI-PubMed.25907407.s4.e2" /></sentence><sentence text=" Following a high-fat meal (study 1), cabozantinib Cmax and AUC were increased (40"><entity charOffset="38-50" id="DDI-PubMed.25907407.s5.e0" text="cabozantinib" /></sentence><sentence text="5% and 57%, respectively), and the median tmax was delayed by 2 hours" /><sentence text=" Cabozantinib should thus not be taken with food (patients should not eat for at least 2 hours before and at least 1 hour after administration)"><entity charOffset="1-13" id="DDI-PubMed.25907407.s7.e0" text="Cabozantinib" /></sentence><sentence text=" In the DDI study (study 2), the 90% confidence intervals (CIs) around the ratio of least-squares means of cabozantinib with esomeprazole versus cabozantinib alone for AUC0-inf were within the 80%-125% limits; the upper 90%CI for Cmax was 125"><entity charOffset="107-119" id="DDI-PubMed.25907407.s8.e0" text="cabozantinib" /><entity charOffset="125-137" id="DDI-PubMed.25907407.s8.e1" text="esomeprazole" /><entity charOffset="145-157" id="DDI-PubMed.25907407.s8.e2" text="cabozantinib" /><pair ddi="false" e1="DDI-PubMed.25907407.s8.e0" e2="DDI-PubMed.25907407.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25907407.s8.e0" e2="DDI-PubMed.25907407.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25907407.s8.e0" e2="DDI-PubMed.25907407.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25907407.s8.e1" e2="DDI-PubMed.25907407.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25907407.s8.e1" e2="DDI-PubMed.25907407.s8.e2" /></sentence><sentence text="1%" /><sentence text=" Because of the low apparent risk of a DDI, concomitant use of PPIs or weaker gastric pH-altering agents with cabozantinib is not contraindicated"><entity charOffset="110-122" id="DDI-PubMed.25907407.s10.e0" text="cabozantinib" /></sentence><sentence text=" " /></document>